In linewith the role of m6A in the cancer immune response, knockingout METTL3 and METTL14 has been shown to enhance the response to immunotherapyby targeting the programmed cell death protein 1 (PD-1) in the contextof melanoma and CRC resistant to immunotherapy, namely, mismatch-repair-proficientor microsatellite instability-low (pMMR-MSI-L). Here, METTL3 is linked to melanoma.